Optimizing Treatment Strategies for Metastatic NSCLC: Achieving the Best Patient Outcomes  : Episode 1

Robert’s Journey With EGFR+ Metastatic NSCLC

December 23, 2024

Opinion

Video

Profiling a 58-year-old retired construction manager with Stage IV EGFR+ NSCLC, discussing his transition from osimertinib to amivantamab plus chemotherapy, managing side effects, and maintaining hope throughout his treatment journey.

Now Viewing

EP: 1.Robert’s Journey With EGFR+ Metastatic NSCLC

EP: 2.Patient Guidance and Education of EGFR Inhibitor Therapies

EP: 3.Strategies to Managing Cardiotoxic AEs with Osimertinib

EP: 4.Balancing Treatment Benefits and Toxicity: Managing Quality of Life in EGFR+ NSCLC Patients

EP: 5.Strategies of Dose Modifications of Osimertinib and Other EGFR Inhibitors

EP: 6.Management of GI Toxicities in Osimertinib and other EGFR Inhibitors

EP: 7.Importance of Multidisciplinary Team in Managing AEs of EGFR Inhibitors

EP: 8.Comparison of Safety Profiles of EGFR Inhibitors

EP: 9.Jason’s Journey with ALK+ Metatstatic NSCLC

EP: 10.Patient Education and Guidance on Lorlatinib and Other ALK Inhibitors

EP: 11.Management of Neurotox AEs with Lorlatinib

EP: 12.Management of Hyperlipidemia and Weight Gain with Lorlatinib

EP: 13.Management of GI AEs with ALK Inhibitors

EP: 14.Dose Modifications When Managing Side Effects with ALK Inhibitors

EP: 15.Role of Multidisciplinary Strategies in care of ALK+ NSCLC Patients

EP: 16.Patient Factors in Treatment Selection of ALK Inhibitors

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!

Latest Conference Coverage

Safety Management With Amivantamab Plus Lazertinib in NSCLC

Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC

Adverse Events of Menin Inhibitors in AML: What Nurses Should Know

Ivonescimab/Chemo Ups PFS After Third-Generation TKI in EGFR+ NSCLC

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777